

## References

Feedback from investigators and KOLs demonstrate excitement surrounding Dren's novel and innovative programs and the potential for addressing patients' unmet needs across several indications.

### DR-01

*“Having consulted and worked with several biotechs and pharma on the development of diagnostic and therapeutic monoclonal antibodies, I have been amazed at the speed and progress of the Dren Bio team. Starting with a discussion in my office at UCSF a week before the COVID shutdown, our collaboration has already resulted in the development of a depleting monoclonal antibody (DR-01) for treatment of certain leukemias and autoimmunity patients that is well along in phase I trials for several indications. I congratulate Nenad Tomasevic and the entire Dren Bio team on their outstanding science and clinical development achievements in this short time.” – Lewis Lannier, UCSF*

*“Dren Bio has made amazing progress in advancement of novel antibody-based therapeutics to the clinic in a very short time. They have pioneered the development of DR-01 to deplete leukemic large granular lymphocytes (LGL). LGL leukemia is a rare disease characterized by clonal expansion of functional cytotoxic cells that leads to cytopenias and autoimmune disorders such as rheumatoid arthritis. This illness is incurable and current immunosuppressive therapy works slowly and is not totally satisfactory. Phase I studies of DR-01 have been very promising with rapid elimination of leukemic cells resulting in clinical benefit for patients in which previous therapies have not worked.” – Thomas Loughran, UVA*

*“We are so excited about the activity we are seeing with DR-01. Everyone wants to be on DR-01 - Jasmin Zain, City of Hope*

*“When can you start this study in Italy. I need this for my patients.” – Pier Luigi, Zinzani, Univeristy of Bologna, Italy*

*“ We are excited about the activity we are seeing in our patients, this is finally a change” – Miles Prince, Peter MacCallum Cancer Center and Epworth Hospital, Melbourne, Australia*

*“You are the trail blazer for these patients, nobody has done a prospective study of that extend in this patient population. You define the path forward.” - Steve Horwitz, MSKCC*

### DR-02 Platform Programs

*“I'm genuinely excited about Dren Bio targeted myeloid engager and phagocytosis platform. It's been a real privilege to help advance DR-0201 into the clinic and explore its potential for achieving deep B-cell depletion and immune reprogramming of myeloid cells. Dren's science is smart, creative, and exactly the kind of innovation the Galien Award was meant to celebrate.” – Miriam Merad, Mount Sinai*

*“ This is one of the most exiting new entities entering the B-NHL in the last few years” – Ajay Gopal, Director of Clinical Research, Hematology Malignancies, FHCC, Seattle*

***“Starting dose escalation based on data from healthy volunteers certainly will help enrollment as we can discuss this study with patients with much greater confidence”***

– Joy Ho, Director of Research, Hematology Institute, Royal Prince Alfred Hospital, Sydney

***“For patients with DLBCL, CD19 CAR T and CD20xCD3 bispecifics have revolutionized the therapy for relapse & refractory patients. However, about half of the patients do not respond and will require a differentiated treatment option. I am excited about your approach”*** – Michael Dickinson, Lead of the Aggressive Lymphoma Disease Group, Peter MacCallum Cancer Center, Melbourne

***“The induction of target independent immunity recall in your syngeneic in-vivo models is a unique differentiation”*** – Richard Furman, Director of CLL Research Center, Cornell University, New York